Toutes les études
Actif, mais pas en recrutementPHASE3INTERVENTIONNEL

A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease

Fabry disease is a rare inherited condition where fatty substances build up inside the body's cells. Over time, this buildup can damage vital organs such as the kidneys and heart. This Phase 3 trial is testing an oral treatment called lucerastat to see how safe and easy to take it is over a longer period. Only adults who have already completed the earlier six-month study (ID-069A301) can take part. In the UK and Europe, people may stay on the study for up to eight years, or until the drug becomes officially available on the NHS. Throughout the trial, doctors will closely check each person's general health, blood, and kidney function. Some men may also have a special check to see if fat levels inside kidney cells have improved.

En un coup d'œil

Statut
Actif, mais pas en recrutement
Phase
PHASE3
Sponsor
Idorsia Pharmaceuticals Ltd.
Objectif d'inscription
107
Démarrer
18 Dec 2018
Achèvement estimé
01 Nov 2029

De quoi parle cette étude ?

Fabry disease is a rare genetic condition caused by a missing or faulty enzyme. Without enough of this enzyme, a fatty substance called Gb3 builds up in cells across the body. Over time, this buildup can cause pain, skin changes, and serious long-term damage to the kidneys, heart, and nervous system. Current standard treatments often require regular hospital visits for intravenous drips (infusions).

Lucerastat is an experimental medicine taken by mouth as a pill. It works differently from infusion therapies by reducing the production of these fatty substances in the first place. This study is an extension study, meaning it is designed to follow people who have already tested the medicine in an earlier trial, to see how it performs over years rather than months.

Finding out if a treatment is safe and well-tolerated in the long run is crucial for lifelong conditions like Fabry disease. Researchers hope that an effective oral tablet could give patients a simpler, more convenient way to manage their condition and protect their organs from damage.

Points clés

  • Tests the long-term safety of an oral treatment for Fabry disease.
  • Only available to people who completed the previous six-month study.
  • Participants may receive the medicine for up to eight years in Europe.
  • Requires regular clinic visits for blood, urine, and organ health checks.
  • Participation is voluntary and you can leave at any time without affecting your NHS care.

Qui peut être éligible ?

This study is only open to adults aged 18 and over who have already taken part in and completed the initial six-month study of lucerastat (known as study ID-069A301). Because of this, people who have not been in that specific trial cannot join.

To be eligible, participants must be generally stable. Women who could become pregnant and fertile men must agree to follow strict contraception rules throughout the study, as the effects of the medicine on an unborn baby are not fully known. Women must also agree to regular urine pregnancy tests.

You cannot join if you are pregnant, planning a pregnancy, or breastfeeding. You will also be excluded if you developed severe medical problems during the previous trial, such as serious kidney failure, acute kidney damage, a stroke, or heart failure that required hospital treatment.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. I am aged 18 or older.
  2. I have Fabry disease.
  3. I fully completed the six-month treatment in the earlier study (ID-069A301).
  4. I am not pregnant, breastfeeding, or planning a pregnancy.
  5. I am willing to follow strict contraception rules during the study.
  6. I did not experience severe heart, stroke, or kidney complications during the previous trial.
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

Taking part involves taking lucerastat capsules by mouth every day at home. You will need to attend regular clinic appointments so the study team can monitor your health. These visits will include physical examinations, blood and urine tests, and monitoring of your heart and kidneys. In Europe, your participation may last for up to eight years (96 months), or until the medicine receives a licence and becomes available. Some male participants who have taken the medicine for at least two years may also be invited to take part in an extra sub-study, which involves a kidney biopsy (taking a tiny sample of kidney tissue) to look closely at fat buildup.

Risques et avantages potentiels

The main potential benefit is continuing to receive an oral treatment that may help control Fabry disease and prevent cell damage, with close medical supervision. However, there may be side effects from taking the drug long-term, some of which may not yet be known. Tests like kidney biopsies also carry small risks of bruising, bleeding, or discomfort. Taking part is completely voluntary. You are free to leave the trial at any point, and choosing to withdraw will never affect your standard NHS care or your relationship with your medical team.

Locations (42)

  • University of Alabama at Birmingham - Nephrology Research Clinic
    Code postal vérifié
    Birmingham, États-Unis
  • University of California Irvine
    Code postal vérifié
    Irvine, United States
  • Hôpital pour enfants UCSF Benioff Oakland
    Code postal vérifié
    Oakland, États-Unis
  • University of Florida Clinical and Translational Science Institute, UF Clinical Research Center
    Code postal vérifié
    Gainesville, États-Unis
  • Rush University Medical Center - Dept of Pediatrics
    Code postal vérifié
    Chicago, États-Unis
  • University of Iowa Stead Family Children's Hospital - Division of Medical Genetics
    Code postal vérifié
    Iowa City, États-Unis
  • Hôpital Général du Massachusetts
    Code postal vérifié
    Boston, États-Unis
  • Infusion Associates
    Code postal vérifié
    Grand Rapids, United States
  • University of Pennsylvania - Dept of Medicine
    Code postal vérifié
    Philadelphie, États-Unis
  • Greenwood Genetics Center
    Code postal vérifié
    Greenville, États-Unis
  • Renal Disease Research Institute LLC
    Code postal vérifié
    Dallas, United States
  • Baylore University Medical Center
    Code postal vérifié
    Dallas, United States

Questions fréquentes

How is lucerastat taken?

Lucerastat is taken as a pill by mouth, rather than as an intravenous drip into a vein.

Can anyone with Fabry disease join this study?

No. This study is strictly an extension trial for adults who already completed the earlier six-month trial (study ID-069A301).

How long will the trial last?

In Europe, participants can take part for up to eight years (96 months), or until the drug becomes commercially available.

Will taking part cost me anything?

No. The trial medicine and all study-related health tests are provided free of charge, and travel expenses are usually covered.

What happens if I decide I want to stop taking part?

You can leave the trial at any time without giving a reason. Your doctors will simply switch you back to standard NHS care.

Comment en savoir plus

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.